Keyword Index for Volume 100

abiraterone 671 absolute risk increase 913 absolute risk reduction 913 accelerated/dose-dense chemotherapy 305 active surveillance 888 acute lymphoblastic leukaemia 1026 acute myeloid leukaemia 1026 acyl-CoA synthetase 1369 acylpeptide hydrolase (ACPH, EC 3.4.19.1) 723 ADCC 113 adenocarcinoma 1400 adenoma 1674 adiposity 578 adjuvant chemotherapy 732 adjuvant radiotherapy 913 adjuvant therapy 1549 adoptive Th1-cell therapy 1135 advanced colorectal cancer 266 advanced stage 1198 adverse effects 1 Africa 799 age at first birth 538, 1832 agent-based model 1917 AKT 649, 782, 1406, 1523 Akt/PKB activation 932 ALA derivatives 723 allelic imbalance 1336 alternative splicing 228 aminolaevulinic acid 723 AML 1343 amosite 1175 amplification 487 anal cancer 693 androgen independent 1784 androgen synthesis 671 aneuploidy 959 angiogenesis inhibitors 1, 865, 971, 1465, 1575, 1617, 1666 animal models 221, 311, 1755 anogenital cancers 527 antibiotics 834 antibody-dependent cellular phagocytosis (ADCP) 113 anti-neoplastic-combined chemotherapy protocols 44 anti-tumour strategy 1755 ApoE: apolipoprotein E 1966 Apollon 739 apoptosis 106, 118, 322, 381, 590, 739, 789, 923, 1068, 1073, 1154, 1347, 1415, 1879 AQP3 1889 aromatase inhibitors 442 arteriogenesis 865 asbestos exposure 1336 Ashkenazi 583 aspirin 551 association studies 993, 1846 asthma 829 astrocytoma 789 ATP7A 96 AU-rich element 1943 Aurora A 959 autocrine 971 autoimmune diseases 817, 822 autophagy 1154